Anebulo Pharmaceuticals Inc. reported cash and cash equivalents of $10.4 million as of September 30, 2025, compared to $11.6 million as of June 30, 2025. Total assets stood at $10.7 million, while total liabilities were $1.0 million. Total stockholders' equity was $9.7 million, down from $11.7 million at the previous fiscal year-end. The company reported a net loss per share of $0.05 for the quarter. During the period, Anebulo initiated dosing in a Phase 1 single ascending dose study of its lead drug candidate, selonabant, in an intravenous formulation for the treatment of acute cannabis-induced toxicity in children.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anebulo Pharmaceuticals Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.